A physiologically-motivated compartment-based model of the effect of inhaled hypertonic saline on mucociliary clearance and liquid transport in cystic fibrosis

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Markovetz, Matthew R ^a   Corcoran, Timothy E ^a,b   Locke, Landon W ^b   Myerburg, Michael M ^b   Pilewski, Joseph M ^b   Parker, Robert S ^a,c,d,e  

^a University of Pittsburgh   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d The CRISMA Laboratory (Clinical Research Investigation and Systems Modeling of Acute illness)   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM CHLORIDE;

ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CYSTIC FIBROSIS; HUMAN; LUNG CLEARANCE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MUCOCILIARY CLEARANCE; PATIENT SELECTION; RESPIRATORY EPITHELIUM; THERAPY EFFECT; WATER ABSORPTION; BIOLOGICAL MODEL; DRUG EFFECTS; HYDRODYNAMICS; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; PATHOPHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, INHALATION; BIOLOGICAL TRANSPORT; CYSTIC FIBROSIS; HUMANS; HYDRODYNAMICS; MODELS, BIOLOGICAL; MUCOCILIARY CLEARANCE; SALINE SOLUTION, HYPERTONIC;

EID: 84910650830     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111972     Document Type: Article

References (29)

1. O'Reilly R, Elphick HE (2013) Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis. Drug Design, Development and Therapy 7: 929-37.
2. Boucher RC (2007) Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends in Molecular Medicine 13: 231-40.
3. Corcoran TE, Thomas KM, Myerburg MM, Muthukrishnan A, Weber L, et al. (2010) Absorptive clearance of DTPA as an aerosol-based biomarker in the cystic fibrosis airway. The European Respiratory Journal 35: 781-6.
4. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, et al. (2006) Mucus clearance and lung function in cystic fibrosis with hypertonic saline. The New England Journal of Medicine 354: 241-50.
5. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, et al. (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine 354: 229-240.
6. Accurso FJ, Rowe SM, Clancy J, Boyle MP, Dunitz JM, et al. (2010) Effect of vx- 770 in persons with cystic fibrosis and the g551d-cftr mutation. New England Journal of Medicine 363: 1991-2003.
7. Bennett WD, Ilowite JS (1989) Dual pathway clearance of 99mtc-dtpa from the bronchial mucosa1,
8. The American review of respiratory disease 139: 1132.
9. Ilowite JS, Bennett WD, Sheetz MS, Groth ML, Nierman DM (1989) Permeability of the bronchial mucosa to 99mtc-dtpa in asthma. American Review of Respiratory Disease 139: 1139-1143.
10. Corcoran TE, Thomas KM, Brown S, Myerburg MM, Locke LW, et al. (2013) Liquid hyper-absorption as a cause of increased DTPA clearance in the cystic fibrosis airway. EJNMMI research 3: 14.
11. Locke L, Myerburg M, Markovetz M, Parker R, Weber L, et al. (2014) Quantitative Imaging of Airway Liquid Absorption in Cystic Fibrosis. European Respiratory Journal: In Press.
12. Eckford PDW, Li C, Ramjeesingh M, Bear CE (2012) Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylationdependent but ATP-independent manner. The Journal of Biological Chemistry 287: 36639-49.
13. Van Goor F, Hadida S, Grootenhuis PDJ, Burton B, Stack JH, et al. (2011) Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proceedings of the National Academy of Sciences of the United States of America 108: 18843-8.
14. Byron P, Patton J (1994) Drug delivery via the respiratory tract. Journal of Aerosol medicine 7: 49-75.
15. Sakagami M, Byron PR, Venitz J, Rypacek F (2002) Solute disposition in the rat lung in vivo and in vitro: determining regional absorption kinetics in the presence of mucociliary escalator. Journal of Pharmaceutical Sciences 91: 594-604.
16. Sakagami M (2006) In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Advanced Drug Delivery Reviews 58: 1030-60.
17. Weber B, Hochhaus G (2013) A pharmacokinetic simulation tool for inhaled corticosteroids. The AAPS Journal 15: 159-71.
18. Sturm R (2012) An advanced stochastic model for mucociliary particle clearance in cystic fibrosis lungs. Journal of Thoracic Disease 4: 48-57.
19. Biddiscombe MF, Meah SN, Underwood SR, Usmani OS (2011) Comparing lung regions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol deposition. Journal of aerosol medicine and pulmonary drug delivery 24: 165-173.
20. Donaldson SH, Corcoran TE, Laube BL, Bennett WD (2007) Mucociliary clearance as an outcome measure for cystic fibrosis clinical research. Proceedings of the American Thoracic Society 4: 399-405.
21. Newman S, Bennett WD, Biddiscombe M, Devadason SG, Dolovich MB, et al. (2012) Standardization of techniques for using planar (2d) imaging for aerosol deposition assessment of orally inhaled products. Journal of aerosol medicine and pulmonary drug delivery 25: S-10.
22. Akaike H (1974) A new look at the statistical model identification. Automatic Control, IEEE Transactions on 19: 716-723.
23. Raue A, Kreutz C, Maiwald T, Bachmann J, Schilling M, et al. (2009) Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood. Bioinformatics (Oxford, England) 25: 1923-9.
24. Hoegger MJ, Fischer AJ, McMenimen JD, Ostedgaard LS, Tucker AJ, et al. (2014) Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science 345: 818-822.
25. Boucher R (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. European Respiratory Journal 23: 146-158.
26. Regnis Ja, Robinson M, Bailey DL, Cook P, Hooper P, et al. (1994) Mucociliary clearance in patients with cystic fibrosis and in normal subjects. American Journal of Respiratory and Critical Care Medicine 150: 66-71.
27. Robinson M, Eberl S, Tomlinson C, Daviskas E, Regnis J, et al. (2000) Regional mucociliary clearance in patients with cystic fibrosis. Journal of Aerosol Medicine 13: 73-86.
28. Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. Journal of Pharmacokinetics and Biopharmaceutics 6: 165-75.
29. Myerburg MM, Harvey PR, Heidrich EM, Pilewski JM, Butterworth MB (2010) Acute regulation of the epithelial sodium channel in airway epithelia by proteases and trafficking. American Journal of Respiratory Cell and Molecular Biology 43: 712-9.